All these therapies present specific problems in terms of unwanted effects and outcome; in particular, proteasome-inhibitors are quite cardiotoxic, rendering them not suitable for the treatment of anti-β1AR-mediated HF [40]. The gene discussed is ADRB1; the disease is hydrops fetalis.